Cell Genesys, Inc. (CEGE-NASDAQ) has done what many small biotechs do that are in need of cash: sell shares in a private placement "PIPE" after a sharp stock run-up. It has entered into definitive agreements with institutional investors to sell 10.8 million shares of its common stock and warrants to purchase 2.2 million shares of its common stock through a registered direct offering for gross proceeds of $60 million, before deducting offering fees and expenses. It also lists Credit Suisse as the lead placement agent for the offering and Needham, Canaccord Adams, and Cantor Fitzgerald are listed as co-placement agents.
The good news is that the funds are all going for what they should be going for: Cell Genesys intends to use the net proceeds from this offering to fund development of its product candidates, including ongoing Phase 3 trials of its lead product, GVAX immunotherapy for prostate cancer, as well as for general corporate purposes. The original shelf offering was made in 2003 and the company has previously raised capital. These shares and warrants will be immediately seperable and the five-year warrants will not be exercisable prior to six months after issuance.
Shares are down 8.5% at $5.56 in pre-market trading after closing down more than 10% yesterday. This can’t be too large of a shock since the company stock has more than doubled in the last 3-weeks after the meteoric rise in Dendreon (DNDN).
Jon C. Ogg
April 11, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.